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Abstract
Background: Despite its reported pro-inflammatory activity, cyclooxygenase (COX)-2 has been
proposed to play a protective role in asthma. Accordingly, COX-2 might be down-regulated in the
airway cells of asthmatics. This, together with results of experiments to assess the impact of COX-
2 blockade in ovalbumin (OVA)-sensitized mice in vivo, led us to propose a novel experimental
approach using house dust mite (HDM)-sensitized mice in which we mimicked altered regulation
of COX-2.
Methods: Allergic inflammation was induced in BALBc mice by intranasal exposure to HDM for
10 consecutive days. This model reproduces spontaneous exposure to aeroallergens by asthmatic
patients. In order to impair, but not fully block, COX-2 production in the airways, some of the
animals received an intranasal antisense oligonucleotide. Lung COX-2 expression and activity were
measured along with bronchovascular inflammation, airway reactivity, and prostaglandin
production.
Results: We observed impaired COX-2 mRNA and protein expression in the lung tissue of
selective oligonucleotide-treated sensitized mice. This was accompanied by diminished production
of mPGE synthase and PGE2 in the airways. In sensitized mice, the oligonucleotide induced
increased airway hyperreactivity (AHR) to methacholine, but a substantially reduced
bronchovascular inflammation. Finally, mRNA levels of hPGD synthase remained unchanged.
Conclusion:  Intranasal antisense therapy against COX-2 in vivo mimicked the reported
impairment of COX-2 regulation in the airway cells of asthmatic patients. This strategy revealed an
unexpected novel dual effect: inflammation was improved but AHR worsened. This approach will
provide insights into the differential regulation of inflammation and lung function in asthma, and will
help identify pharmacological targets within the COX-2/PG system.
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Background
The synthesis of prostaglandins (PG) is catalyzed by either
cyclooxygenase (COX)-1 or COX-2, and COX-2 is known
to be up-regulated in inflammatory diseases [1]. Although
COX-2 and PGs would therefore be expected to be overex-
pressed in asthma, many observations suggest that this is
not always the case. For instance, reports have shown
unchanged levels of PGE2 in the exhaled breath of asth-
matic patients [2], and reduced PGE2 and COX-2 levels in
smooth muscle cells [3]. Low PGE2 production [4] and
COX-2 down-regulation [4-7] have been reported in the
nasal polyps of asthmatics, in whom the COX-2 up-regu-
lation rate has decreased [6], an observation also inferred
from studies in a horse model of asthma [8]. These data
suggest that COX-2 may in fact play a protective role in
asthma through the production of anti-inflammatory
prostanoids [9,10]. This hypothesis is supported by clini-
cal studies in which exogenous PGE2 prevented asthmatic
responses induced by aspirin, exercise, and allergens [11-
13], and by our experiments in house dust mite (HDM)-
sensitized mice, in which exogenous PGE2 exerted an anti-
inflammatory effect [14]. PGI2 might also contribute to
the anti-asthmatic effects of COX-2 [15], whereas PGD2 is
mainly considered to favor asthma [16], despite recent
evidence to the contrary [17]. It is difficult to account for
the defensive properties of COX-2, with results pointing
to increased activity of this enzyme in asthma [18-21], but
it is likely that the COX-2/PG system functions as a com-
plex network that modulates the asthmatic response
according to its fluctuating expression throughout the
course of the disease [9]. An accurate understanding of
this system could provide novel pharmacological targets
[22]. In ovalbumin (OVA)-sensitized mice, the results of
the blockade of COX-2 activity provide partial support for
a protective role of the enzyme. The number of inflamma-
tory cells in the airway remains unaltered [23] or increases
to varying degrees in response to pharmacological inhibi-
tion [24-28] or genetic disruption of COX-2 [23,27]. Only
Peebles and co-workers and our group [24-26,28] have
detected worsening of airway hyperreactivity (AHR).
Despite their value, none of the procedures reproduced
the reported impaired capacity of asthmatic airways to
produce COX-2 [4-7]. Instead, they either induced full
blockade (genetic deletion) or reduced activity (inhibi-
tors) of the enzyme. In an attempt to faithfully mimic
events in asthmatics, we chose a recently established
HDM-induced mouse model of asthma [29], in which we
selectively impaired the production of COX-2 in the air-
ways through the use of an antisense oligonucleotide. We
then assessed the impact of COX-2 down-regulation on
airway inflammation, lung function, and PG production.
Materials and methods
Exposure to house dust mite extract
Adult female BALBc mice aged 6 to 8 weeks (Harlan Iber-
ica, Barcelona, Spain) were used in the study. All animal
procedures were approved by the Ethics Committee for
Animal Research of the Universitat Autònoma de Barce-
lona.
Sensitization to HDM was induced following a procedure
established by Cates et al. [29]. Briefly, the mice were
exposed to purified HDM extract (Alk-Abelló, Madrid,
Spain) with a very low LPS content (<0.2 EU/dose, meas-
ured using the Charles River Endosafe Limulus Amebo-
cyte Assay (Charles River Laboratories, Wilmington,
Massachusetts, USA). The allergen was administered intra-
nasally under light halothane anesthesia for 10 consecu-
tive days at a dose of 25 μg/mouse in a 20-μl volume.
Non-sensitized (control) animals received intranasal
saline.
Antisense oligonucleotide administration
An antisense oligonucleotide strategy was used to selec-
tively down-regulate the production of lung COX-2
mRNA but not COX-1 mRNA. One day before initiating
exposure to HDM, and up to two days after withdrawing
the allergen, the mice received intranasal saline
(untreated), control mismatched antisense oligonucle-
otide, or selective COX-2 antisense oligonucleotide at 20
μg/mouse (Figure 1). On the days both products were
administered, the treatment was always provided one
hour before administering the HDM extract. The COX-2-
selective oligonucleotide sequence (IK6 antisense oligo-
nucleotide, 5'GGAGTGGGAGGCACTTGC3') was taken
from Khan et al. [30]. The control oligonucleotide con-
tained a 7-base mismatched sequence (5'GGACTAGGTTC
AAGTTGC3'). Both oligonucleotides were synthesized
with a phosphorothioate backbone to improve resistance
to endonucleases. Four experimental groups of mice were
therefore established (n = 12 per group): (1) untreated
non-sensitized, (2) untreated HDM-sensitized, (3) HDM-
sensitized treated with a non-specific control oligonucle-
otide, and (4) HDM-sensitized treated with an antisense
oligonucleotide targeting COX-2. For COX-2 mRNA
expression, an additional group was included: non-sensi-
tized treated with the COX-2-targeted antisense oligonu-
cleotide (n = 12).
COX-2 mRNA expression in the lung
COX-2 mRNA expression in the lung was assessed by real
time PCR. Total RNA was extracted using Trireagent
(Molecular Research Center Inc, Cincinnati, Ohio, USA),
and traces of contaminating genomic DNA were removed
with DNAfree (Ambion Inc, Austin, Texas, USA). COX-2
cDNA was generated using MMLV reverse transcriptase
(Epicentre, Madison, Wisconsin, USA). For real-time PCR,Respiratory Research 2008, 9:72 http://respiratory-research.com/content/9/1/72
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2 μg of total RNA from each animal was reverse tran-
scribed and the resulting cDNA was placed in the glass
capillaries together with 18 μl of a master mix. The COX-
2 primers were designed with PrimerSelect software
(DNASTAR Inc, Madison, Wisconsin, USA) and were as
follows: forward primer, 5'AGCCAGCAAAGCCTAGAGC
AACAA3'; and reverse primer, 5'TGACCACGAGAAACGG
AACTAAGAGG3'. PCR was performed in a LightCycler
instrument and the crossing point (defined as the point at
which fluorescence increases appreciably above back-
ground fluorescence) was determined with LightCycler
software (both from Roche Diagnostics, Mannheim, Ger-
many) using the second derivative maximum method.
Using the Relative Expression Software Tool (REST©), the
relative expression ratio was calculated on the basis of
group means for COX-2 as the target gene versus the refer-
ence gene GAPDH, and the calculated group ratio was
tested for significance using a statistical model known as
the Pair Wise Fixed Reallocation Randomization Test©
[31]. We took into account the PCR efficiency calculated
for COX-2 and GAPDH, which was very similar for both.
For purposes of graphical representation, the COX-2
mRNA expression ratio of the non-sensitized untreated
mice was established as 1.0, and the average ratios of the
other experimental groups were re-calculated on that
basis.
COX-2 protein expression and activity in the lung
To support lung COX-2 mRNA assessment, the enzyme's
airway protein expression and activity were determined in
some of the mice from each experimental group (from 3
to 6 mice see legend of Figure 2b and 2c). Briefly, proteins
were extracted from the right lung lobe of each animal
using a lysis buffer containing protease inhibitors (Mini
complete tablet, Roche Diagnostics, Mannheim, Ger-
many). The concentration of COX-2 protein was deter-
mined by ELISA (IBL, Hamburg, Germany).
Immunohistochemistry for COX-2 was performed in lung
sections using a polyclonal antibody (sc-1746, Santa Cruz
Biotechnology, Santa Cruz, California, USA) after boiling
in 10 mM citrate buffer (pH 6) to retrieve the antigen. The
sections were then incubated overnight at 4°C with or
without the primary antibody. A rabbit anti-goat second-
ary antibody (Vector, Burlingame, California, USA) was
used at room temperature for 1 hour, followed by incuba-
tion with horseradish peroxidase-conjugated avidin-
biotin complex (Pierce, Rockford, Illinois, USA). Staining
was then performed with diaminobenzidine to reveal
immunolabeling. Additionally, prostanoids were
extracted from BAL fluid and purified through Sep-Pak
C18 columns (Waters Corporation, Milford, Massachu-
setts, USA). After evaporation and resuspension in EIA
buffer, the PGE2  concentration was measured using a
commercially available specific ELISA (Cayman Europe,
Tallin, Estonia).
Pulmonary function testing
To assess the effect of impaired COX-2 production on air-
way function, we analyzed the in vivo airway reactivity to
increasing doses of nebulized methacholine (6.25 to 100
mg/ml) 24 hours after the last exposure to HDM in either
Sensitization protocol and antisense oligonucleotide (ASO) administration Figure 1
Sensitization protocol and antisense oligonucleotide (ASO) administration. Oligonucleotide was administered 
intranasally one hour before house dust mite (HDM). Twenty-four hours after the last challenge, pulmonary function was 
assessed by unrestrained whole body plethysmography. Animals were sacrificed the following day and samples were taken.
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(a). Relative expression of COX-2 mRNA in lung tissue from different treatment groups assayed by real-time PCR Figure 2
(a). Relative expression of COX-2 mRNA in lung tissue from different treatment groups assayed by real-time 
PCR. The mRNA expression ratio in the non-sensitized mice was established as 1.0. The level of COX-2 mRNA was signifi-
cantly diminished in the lungs of sensitized mice treated with the selective antisense oligonucleotide (ASO) when compared 
with both untreated and control oligonucleotide-treated sensitized mice (n = 12). 2 (b). Levels of COX-2 protein in the lung 
tissue of non-sensitized mice (n = 3) and in untreated and COX-2 ASO-treated HDM-sensitized mice (n = 6). 2 (c) PGE2 con-
tent in the bronchoalveolar lavage (BAL) of non-sensitized (n = 1) and HDM-sensitized treated (n = 4) and untreated (n = 3) 
mice (* p < 0.05). MM, mismatched oligonucleotide.
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treated or untreated sensitized and non-sensitized mice
(Figure 1), using a well established [32-34] non-invasive
whole-body plethysmography (WBP) technique (Buxco
Europe Ltd, Winchester, UK), which is based on changes
in the time elapsed between nasal and thoracic pressure
fluctuations. The response to methacholine was averaged
and expressed as Penh (Enhanced Pause) as previously
reported [14]. Results were compared by two-way
ANOVA. In the BALB/c mice strain, Penh has been shown
to correlate with lung mechanics (RL) [35]. This can also
be inferred from recent studies, in which AHR was
assessed using WBP in combination with invasive proce-
dures [36,37].
Assessment of airway inflammation
Inflammation was evaluated 48 hours after the last expo-
sure to HDM (Figure 1) using two approaches. Total cel-
lularity in BAL samples was counted immediately after
fluid collection. BAL was performed by slowly infusing
0.3 ml of phosphate-buffered saline (PBS) (2% fetal
bovine serum) twice and recovering it by gentle aspiration
30 seconds after delivery. A 20-μl aliquot of BAL fluid was
stained with Turk solution (0.01% crystal violet in 3%
acetic acid) and analyzed in a Neubauer chamber. In addi-
tion, an experienced blinded observer counted the
number of Congo red-stained eosinophils twice in histo-
logical lung sections of the same animals. The tissue area
was also measured using MIP 45 Advanced System image
analysis software (Microm España, Barcelona, Spain) to
express the number of eosinophils per mm2. Group
means (n = 12) were compared using an unpaired t test.
Expression of mPGE synthase and hPGD synthase in the 
lung
The expression of mPGE synthase and hPGD synthase was
determined by conventional reverse transcriptase-PCR
using previously described primer pairs [38] in mRNA
extracted from the lungs. GAPDH was assessed as the ref-
erence gene. Samples were denatured for 5 min at 95°C,
and the cycling parameters (35 cycles) for mPGES,
hPGDS, and GAPDH were 95°C for 30 sec, 55°C for 30
sec, and 72°C for 30 sec. A final extension step of 8 min
at 72°C was applied. Amplification products were sepa-
rated by agarose gel electrophoresis. After staining with
ethidium bromide, the optical density of the bands was
analyzed using Quantity One software (Bio-Rad Laborato-
ries, Hercules, California, USA). The ratios of the band
densities were calculated for each enzyme versus GAPDH
and the means (n = 12) were compared using an unpaired
t test.
Statistical analysis
Data in the text, table, and figures are expressed as the
mean ± standard error of the mean (SEM) unless other-
wise stated. Differences in airway response between differ-
ent groups were tested for statistical significance using
ANOVA followed by a post hoc Bonferroni test. The
unpaired t test was used for all other analyses. Differences
were considered statistically significant when the proba-
bility value was less than 0.05.
Results
Intranasal antisense oligonucleotide impairs pulmonary 
COX-2 expression and activity
Figure 2a shows the relative expression ratio of COX-2
mRNA in lung tissue, where 1.0 was established as the
baseline level in the untreated non-sensitized mice. The
level in the lung tissue of HDM-sensitized mice treated
with the control oligonucleotide was the same as in the
lung tissue of the untreated sensitized mice. In contrast,
COX-2 mRNA expression was significantly diminished in
sensitized mice treated with the COX-2-specific antisense
oligonucleotide compared with untreated (55% decrease)
or mismatched control oligonucleotide-treated HDM-
sensitized mice. In the non-sensitized mice's airway, the
antisense oligonucleotide did not exert any effect on
COX-2 mRNA expression. Our data also revealed that
there were no statistically significant differences in the
expression of lung COX-2 between non-sensitized and
HDM-sensitized mice.
The concentration of COX-2 in lung protein extracts from
some of the mice was measured by ELISA. A significant
45% reduction in COX-2 protein concentrations was
observed in the lungs of COX-2 antisense-treated sensi-
tized mice compared with non-treated sensitized mice
(Figure 2b). Analysis of COX-2 expression in the lung by
immunohistochemistry showed the same results for
untreated HDM-sensitized mice and mismatched control
oligonucleotide-treated sensitized mice (Figure 3e), that
is, they consistently had a visibly increased number of
positive cells and a stronger staining intensity than selec-
tive COX-2 oligonucleotide-treated mice (Figure 3f).
The photomicrographs in Figure 3 also show that the pat-
tern of COX-2 expression in the airways of the mice was
restricted to secondary and tertiary bronchi and bronchi-
olar epithelial cells (Figure 3a and 3b), as well as alveolar
macrophages (Figure 3c). No expression whatsoever was
observed in the epithelium of the main bronchi in any of
the animals studied. This distribution pattern of COX-2
protein was found to be identical in all the experimental
groups, regardless of whether they were sensitized or not,
or treated or not. Only representative pictures of the pat-
tern are included.
Finally, the PGE2 concentration in BAL fluid was signifi-
cantly (66%) lower in the lungs of COX-2 antisense oligo-
nucleotide-treated sensitized mice than in the untreated
sensitized ones (Figure 2c). Thus, impairment of COX-2Respiratory Research 2008, 9:72 http://respiratory-research.com/content/9/1/72
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expression was accompanied by a similar level of
impaired activity.
Selective impairment of pulmonary COX-2 increases 
airway hyperreactivity
Increasing doses of methacholine induced a dose-depend-
ent rise in Penh in all experimental groups (Figure 4). The
Penh increase was higher in the HDM-sensitized mice
than in the non-sensitized mice, revealing the induction
of AHR in the HDM-sensitized animals. As shown in Fig-
ure 4, untreated and control oligonucleotide-treated sen-
sitized mice had almost identical responses to the
bronchoconstrictor. However, AHR was significantly
higher in the selective COX-2 oligonucleotide-treated
Photomicrographs of COX-2 immunolabeling in lung samples from HDM-sensitized mice following different treatments Figure 3
Photomicrographs of COX-2 immunolabeling in lung samples from HDM-sensitized mice following different 
treatments. Pictures a, b, and c show representative images of the COX-2 immunostaining pattern in the airways. Since the 
COX-2 distribution was almost the same in all 4 experimental groups, only representative images of one of them are included. 
3 (a) shows a general view of COX-2 distribution in the airways, where labeling is detected in the bronchiolar epithelium but 
not in the principal airway. 3 (b) shows a single bronchiole (magnified view of the area outlined in [a]), and 3 (c) shows stained 
alveolar macrophages. Pictures d, e, and f reflect the consistent changes in the COX-2 antigen signal intensity under different 
experimental conditions. 3 (d) shows a single bronchiole from a non-sensitized mouse, 3 (e) A single bronchiole from a sensi-
tized mouse treated with control mismatched oligonucleotides (MM), and 3 (f) COX-2 protein expression in the airways after 
treatment with the COX-2 antisense oligonucleotide (ASO). Similar staining intensity was seen in untreated sensitized mice, in 
which cells were heterogeneously labeled and peribronchial and perivascular inflammation was observed, but the immunostain-
ing signal diminished clearly and consistently in the treatment group.Respiratory Research 2008, 9:72 http://respiratory-research.com/content/9/1/72
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mice, where the Penh value at the maximum metha-
choline concentration (100 mg/ml) was almost twice that
found in the untreated or mismatched control-treated
sensitized animals (7.40 ± 1.62 vs 14.12 ± 2.75).
Selective impairment of pulmonary COX-2 reduces airway 
inflammation
HDM-sensitized mice developed a clear peribronchial and
perivascular eosinophilic inflammation (Figure 3e) with
goblet cell hyperplasia, compared with the non-sensitized
animals. No differences were found in the total number of
inflammatory cells or in eosinophil accumulation
between untreated and mismatched control oligonucle-
otide-treated sensitized animals (Figure 5a and 5b). In
contrast, when COX-2 was selectively inhibited in sensi-
tized mice, the level of inflammation was clearly and sig-
nificantly reduced to 50%–55% of its value in the
untreated HDM-sensitized mice, depending on whether
total cells or eosinophils were considered (Figure 5a and
5b, respectively). This reduced inflammation was also vis-
ible in the lung sections (Figure 3f).
Selective blockade of pulmonary COX-2 inhibits mPGE2 
synthase but not hPGD2 synthase
The mRNA expression of mPGE2 and hPGD2 was normal-
ized to the level of constitutive GAPDH (Table 1). No dif-
ferences were observed between the non-sensitized and
the untreated sensitized mice. The expression ratio in the
untreated and the mismatched control oligonucleotide-
treated mice was also the same for both enzymes. Like-
wise, no differences were found in the mRNA expression
of hPGD2 synthase in the lungs of mice from any of the
Airway reactivity to increasing concentrations of aerosolized methacholine Figure 4
Airway reactivity to increasing concentrations of aerosolized methacholine. Airway reactivity is shown in non-sen-
sitized mice (white circles), untreated sensitized mice (white squares), control mismatched oligonucleotide-treated sensitized 
mice (grey squares), and selective COX-2 antisense sensitized mice (black squares). Two-way analysis of variance was used to 
compare the curves. The COX-2 antisense oligonucleotide (ASO)-treated mice showed a significant increase in AHR to meth-
acholine compared with both untreated and control oligonucleotide-treated sensitized mice. Data are shown as the mean ± 
SEM (**p < 0.01, ***p < 0.005). ASO: antisense oligonucleotide, MM: mismatched oligonucleotide (n = 12).
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experimental groups, whether or not they were treated
with COX-2 antisense oligonucleotide. In contrast, HDM-
sensitized mice treated with the selective COX-2 oligonu-
cleotide displayed significantly reduced expression of
mPGE synthase (40% reduction) compared with mis-
matched control oligonucleotide-treated or untreated sen-
sitized animals.
Discussion
This study shows that intranasal administration of a selec-
tive COX-2 antisense oligonucleotide impairs COX-2
expression and activity in the lungs, and that this change
has a fairly unusual effect on the airway response of HDM-
sensitized mice, namely, AHR worsens while airway
inflammation improves. This COX-2-driven modulation
is associated with reduced ability of airway cells to synthe-
size PGE2, but apparently not PGD2, as might be deduced
from the expression of the corresponding PG synthases.
To our knowledge, this is the first study in which COX
production has been impaired using antisense technology
in a murine model of asthma. Rather than induce com-
plete inhibition of COX-2 production or impair its activ-
ity, the inhibitory strategy used in our experiment was
intended to mimic the described reduced production of
COX-2 [5-7] and hence PG [4,8,39] in asthma. Since there
Airway inflammation in non-sensitized and in untreated or treated HDM-sensitized mice Figure 5
Airway inflammation in non-sensitized and in untreated or treated HDM-sensitized mice. Graph (a) shows the 
total inflammatory cell count in bronchoalveolar lavage fluid, and graph (b) depicts the eosinophils infiltrating the airways in the 
same animals. In both cases, the selective COX-2 antisense oligonucleotide caused a significant reduction in the accumulation 
of inflammatory cells in the lungs. No differences were found between the untreated and the control mismatched oligonucle-
otide-treated sensitized mice. Data are shown as means ± SEM (*p < 0.05, **p < 0.01). ASO: antisense oligonucleotide, MM: 
mismatched oligonucleotide (n = 12)
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Table 1: Expression ratio of mPGE synthase and hPGD synthase mRNA in lung tissue from different treatment groupsa
Expression ratio Non-sensitized Untreated HDM-sensitized MM ASO HDM-sensitized COX-2 ASO HDM-sensitized
mPGE synthase/GAPDH 1.105 ± 0.09 1.047 ± 0.09 1.068 ± 0.13 0.624 ± 0.13*
hPGD synthase/GAPDH 0.369 ± 0.06 0.417 ± 0.06 0.335 ± 0.05 0.365 ± 0.06
a mRNA expression was analyzed by conventional reverse transcriptase-polymerase chain reaction and the expression ratios compared with 
GAPDH were determined by densitometry. No differences were observed in hPGD synthase mRNA expression, either between non-sensitized 
and sensitized animals or between HDM-sensitized animals treated with mismatched antisense oligonucleotides and animals treated with COX-2 
antisense oligonucleotide. In contrast, mPGE synthase expression was reduced in the selective COX-2 oligonucleotide-treated mice compared with 
the other experimental groups. Data are shown as the mean ± SEM (*p< 0.05). ASO, antisense oligonucleotide; MM, mismatched oligonucleotide (n 
= 12).Respiratory Research 2008, 9:72 http://respiratory-research.com/content/9/1/72
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were no previous records on the ideal conditions of intra-
nasal administration of the anti-COX-2 oligonucleotide,
we chose the most efficient sequence used in another bio-
logical system in which it had been optimized to guaran-
tee an effect [30]. Our goal was to ensure efficient down-
regulation of COX-2 mRNA during the relevant phases of
sensitization and challenge. In contrast to systemic inhibi-
tion of the enzyme [23-27], in our experiment the block-
ing agent was delivered within the airway, a strategy that
most likely restricts its effects to the lungs [40]. Finally, the
use of a natural aeroallergen, and its daily administration
exclusively through the airways, allows an accurate repro-
duction of the exposure in humans. Therefore we feel that
ours is an extremely suitable approach to determine the
role of COX-2 during the course of asthma.
To validate our inhibitory strategy, we analyzed lung
COX-2 mRNA expression. Furthermore, the COX-2
mRNA data were supported by the analysis of airway
COX-2 protein expression and the assessment of its activ-
ity by measuring the production of one of its main prod-
ucts, PGE2 [41]. Irrespective of the variable considered, the
degree of inhibition of airway COX-2 achieved with anti-
sense oligonucleotide treatment was between 45% and
66%. Although immunohistochemistry is not a quantita-
tive technique, we could consistently identify a stronger
COX-2 antigen signal in the airway of mice not receiving
the antisense oligonucleotide. In addition, since immu-
nohistochemistry revealed that COX-2 expression was
consistently restricted to the bronchial epithelium of the
lower airways, we can be fairly certain that the method
used to deliver the oligonucleotide reached deep areas of
the bronchial tree. This is not surprising, since intranasal
provision of siRNA targeting other molecules has been
shown to affect the alveoli [42]. The restricted expression
of COX-2 in the lower airways of non-asthmatic animals
is consistent with a previous observation in healthy mice
[43].
Interestingly, lung COX-2 mRNA from non-sensitized
mice was not affected by the antisense oligonucleotide,
suggesting a differential effect of the oligonucleotide in
allergen-sensitized and non-sensitized scenarios, a
hypothesis that would require specific validation. Accord-
ingly, it is noteworthy that, although COX-2 expression
was not significantly increased in sensitized versus non-
sensitized mice, there was a trend towards up-regulation.
However, if any, the overproduction of COX-2 is mild in
the HDM-sensitized animals. Although these results
appear to contradict previous data [18-21], they are plau-
sible in the light of other observations in patients in
whom exhaled PGE2  remains unchanged [2], and in
whom COX-2 production may even be impaired [3-7].
These discrepancies favor the hypothesis of fluctuating
enzyme activity during the course of the disease [9], as
suggested in other models [44].
The impairment of COX-2 expression and activity caused
by the antisense oligonucleotide was associated with a
worsening of AHR. Pulmonary function was evaluated
using WBP, a method that has been shown to correlate
with lung resistance in BALB/c mice [35], and whose
validity is endorsed by recent publications [36,37,45],
although it has also come under criticism [46]. Therefore,
COX-2 products appear to limit the HDM-induced AHR
and play a protective role at the airway functional level.
The resulting reduced production of endogenous PGE2
and mPGE synthase may be directly linked to the
observed worsening of AHR according to previous obser-
vations [13]. Using an alternative experimental approach,
Peebles et al. [26] showed an IL-13-dependent increased
AHR under COX-2 inhibition in OVA-sensitized mice. We
presume that this Th2  cytokine might at least partly
explain our increased AHR [29], but other elements, such
as cys-leukotrienes, which presumably are increased when
the COX pathway is partly blocked, should not be ruled
out as directly responsible for the in vivo worsening of air-
way function in the presence of antisense oligonucleotide
targeting COX-2 [47,48].
Our data contrast with the findings of other groups
[23,27]. The differences are probably attributable to meth-
odological issues, including their use of a full COX-2
blockade (gene knockout strategy) compared with our
partial blockade through interference with transcriptional
events.
We would have expected the worsening of AHR to be par-
alleled by increased airway inflammation. However, eosi-
nophilic inflammation in COX-2 antisense
oligonucleotide-treated sensitized mice fell to 50% of the
inflammatory burden in untreated HDM-sensitized mice.
Thus, under our conditions, COX-2 products appear to
enhance proinflammatory signals. PGE2 could also be
responsible for such an effect, since in vitro and ex vivo
data suggest that this PG contributes to migration of mast
cells and dendritic cells and, therefore, promotes inflam-
mation [49,50]. However, we believe that a more complex
mechanism involving more than one agent contributes to
such a beneficial antisense oligonucleotide-driven effect.
It has been shown in a rat model of acute lung injury that
inflammation worsened when COX-2 was down-regu-
lated [51]. The opposing actions of COX-2 transcription
impairment on AHR and inflammation are difficult to
interpret. There is a general belief that AHR at least partly
correlates with the underlying inflammatory process,
since respiratory dysfunction is normally accompanied by
airway inflammation in humans and in murine models.
Even though reports have been published in which AHRRespiratory Research 2008, 9:72 http://respiratory-research.com/content/9/1/72
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and inflammation did not fluctuate in parallel [23,52,53],
to our knowledge, an inverse correlation of the magnitude
seen here has not been previously reported. A change in
airway smooth muscle reactivity with no underlying
changes in airway inflammation, or vice versa, can cer-
tainly be interpreted as the result of different mechanisms
leading to two dissociated phenomena. However, our
data raise a different hypothesis; AHR and inflammation
can be differentially modulated to the extent that
impaired COX-2 production leads to a negative correla-
tion between them, and this therefore raises the possibil-
ity of an inverse association of both phenomena, rather
than a dissociation. The use of an antisense oligonucle-
otide targeted to COX-2 administered intranasally in
HDM-sensitized mice has uncovered a key element in
establishing the mechanisms involved in COX-PG-con-
trolled alteration of the asthma response.
Finally, it is noteworthy that our unchanged levels of
hPGD synthase suggest that PGD2 production was proba-
bly unaffected [54], and, therefore, that the impact of this
PG on the oligonucleotide-induced changes was limited.
Despite the fact that PGD2 is usually considered relevant
immediately after challenge [16,55], we measured the
synthase 48 hours after the last exposure to the allergen, a
factor that may explain our negative results.
Conclusion
Administration of antisense oligonucleotides provides a
fairly accurate way to target a single molecule within the
airway environment while minimizing unwanted sys-
temic effects. This interesting model allows us to address
the potentially inadequate regulation of COX-2 in asth-
matic patients. Although our data confirm the protective
effect attributable to COX-2 products in relation to airway
function, they also highlight a role for COX-2 in the gen-
eration of proinflammatory signals. How and when these
opposing functions occur should be the focus of future
research to identify potential pharmacological targets in
the COX-2/PG system.
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